CD274 and cancer: Although immunotherapy, especially through the blockade of immune checkpoints such as programmed death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1), has been widely applied in the treatment of a broad range of human cancers, the proportion of responsive patients experiencing immunologic eradication of cancer remains limited (1).